2,459.80
+31.90
+(1.31%)
As of 10:50:33 AM GMT+5:30. Market Open.
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
116,410,346
103,347,746
87,494,330
77,815,550
62,144,310
Cost of Revenue
34,187,801
32,685,501
29,623,271
24,700,080
18,249,790
Gross Profit
82,222,545
70,662,245
57,871,059
53,115,470
43,894,520
Operating Expense
56,824,205
48,319,305
41,498,318
34,334,160
27,829,910
Operating Income
25,398,340
22,342,940
16,372,741
18,781,310
16,064,610
Net Non Operating Interest Income Expense
-2,097,845
50,055
-330,004
-468,800
171,450
Pretax Income
25,858,482
23,993,582
16,712,391
19,745,990
16,916,110
Tax Provision
5,227,865
4,575,865
3,615,633
5,216,430
3,985,770
Net Income Common Stockholders
20,414,267
19,128,967
12,818,591
14,334,750
12,654,270
Diluted NI Available to Com Stockholders
20,414,267
19,128,967
12,818,591
14,334,750
12,654,270
Basic EPS
50.90
47.75
32.00
35.78
31.59
Diluted EPS
50.81
47.68
32.00
35.78
31.59
Basic Average Shares
401,038.69
400,588.44
400,588.44
400,588.44
400,588.44
Diluted Average Shares
401,738.71
401,167.34
400,588.44
400,588.44
400,588.44
Rent Expense Supplemental
--
232,124
204,261
212,570
179,350
Total Expenses
91,012,006
81,004,806
71,121,589
59,034,240
46,079,700
Net Income from Continuing & Discontinued Operation
20,414,267
19,128,967
12,818,591
14,334,750
12,654,270
Normalized Income
19,497,624.24
18,199,143.62
12,669,988.94
13,609,810.41
12,366,335.81
Interest Income
--
400,510
127,641
129,230
383,020
Interest Expense
2,433,895
285,995
402,736
557,800
193,030
Net Interest Income
-2,097,845
50,055
-330,004
-468,800
171,450
EBIT
28,292,377
24,279,577
17,115,127
20,303,790
17,109,140
EBITDA
33,395,914
28,262,114
20,374,322
21,969,990
18,298,850
Reconciled Cost of Revenue
34,187,801
32,685,501
29,623,271
24,700,080
18,249,790
Reconciled Depreciation
5,103,537
3,982,537
3,259,195
1,666,200
1,189,710
Net Income from Continuing Operation Net Minority Interest
20,414,267
19,128,967
12,818,591
14,334,750
12,654,270
Total Unusual Items Excluding Goodwill
1,148,923
1,148,923
189,616
985,240
376,680
Total Unusual Items
1,148,923
1,148,923
189,616
985,240
376,680
Normalized EBITDA
32,246,991
27,113,191
20,184,706
20,984,750
17,922,170
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
232,280.24
219,099.62
41,013.94
260,300.41
88,745.81
3/31/2021 - 5/9/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BALAXI.NS Balaxi Pharmaceuticals Limited
66.45
-0.76%
TORNTPHARM.BO Torrent Pharmaceuticals Limited
3,237.40
+0.38%
FDC.NS FDC Limited
420.90
-0.96%
GLENMARK.BO Glenmark Pharmaceuticals Limited
1,359.10
-1.19%
LUPIN.BO Lupin Limited
2,012.20
+0.01%
HESTERBIO.NS Hester Biosciences Limited
1,766.60
+1.94%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,229.30
+0.23%
BAJAJHCARE.NS Bajaj HealthCare Limited
620.15
-0.21%
MOREPENLAB.BO Morepen Laboratories Limited
52.45
+0.11%
GLAND.BO Gland Pharma Limited
1,429.60
+0.21%